Print this page Email this page | Users Online: 402
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2023  |  Volume : 14  |  Issue : 1  |  Page : 33-40

REMARK scoring of biomarkers predicting lymph node metastasis in oral squamous cell carcinoma – A systematic review


1 Department of Oral and Maxillofacial Pathology, Government Dental College and Hospital, Nagpur, Maharashtra, India
2 Department of Critical Care Medicine, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
3 Product Manager, Mastercard, Vadodara, Gujarat, India

Correspondence Address:
Dr. Riya Jain
Department of Oral and Maxillofacial Pathology, Government Dental College and Hospital, Medical Square, Nagpur - 440 003, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/srmjrds.srmjrds_116_22

Rights and Permissions

Background: A universal and systematic protocol is essential for accurate reporting of biomarker studies. For unity in reporting biomarker studies, many guidelines were introduced, Recommendations for Tumor Marker Prognostic Studies (REMARK) being one of them. Aim: The purpose of this review is to evaluate the quality of published articles of biomarkers that predict metastasis in lymph nodes in oral squamous cell carcinoma (OSCC) by the use of the reporting recommendations for tumor marker prognostic (REMARK) guidelines. Methods: Comprehensive search was done in MEDLINE via PubMed and Cochrane from January 2015 to December 2019 to identify manuscripts evaluating biomarkers predicting lymph node metastasis in OSCC. The significance of the univariate and multivariate analysis was assessed for each manuscript, and P < 0.05 was considered statistically significant. Results: Thirty-six results were included for the qualitative synthesis. The mean REMARK score was 11.13 (range: 5.01–17.15). Biomarkers with the highest REMARK score were phospholipase C, cyclin D, CD44+/CD133+, and matrix metalloproteinase-9 (MMP-9). While biomarkers such as LGALS1, NCOA7, and TMOD1 were associated with high risk of bias, hence its use as a biomarker predicting lymph node metastasis is questionable. Conclusions: In our review of 36 manuscripts, manuscripts examining biomarkers evaluating lymph node metastasis in OSCC need an improvement in their reporting. Biomarkers such as phospholipase C, cyclin D, CD44+/CD133+, and MMP-9 can be used as a predictor of lymph node metastasis in OSCC.


[FULL TEXT] [PDF]*
Print this article     Email this article
Next article
Previous article
Table of Contents

Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Citation Manager
Access Statistics
Reader Comments
Email Alert*
Add to My List*
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed94    
    Printed0    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    

Recommend this journal